Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
Pubmed

Analysis of the DNA sequence and duplication history of human chromosome 15.

GOLGA6L6 GOLGA6L22

7.09e-05568216572171
Pubmed

EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.

GOLGA6L1 SMC3

3.71e-041288223858473
Cytoband15q11.2

GOLGA6L1 GOLGA6L6 GOLGA6L22

2.85e-061728315q11.2
CytobandEnsembl 112 genes in cytogenetic band chr15q11

GOLGA6L1 GOLGA6L6 GOLGA6L22

5.73e-0621783chr15q11
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

GOLGA6L6 GOLGA6L22

2.51e-041368282b1d6d839c0d0c68e0960549f688138479defcc
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

GOLGA6L6 GOLGA6L22

2.55e-04137820aa4e14b32da0cda677cc0ed6ae470f6ecd77bea
ToppCell3'_v3-Lung-Lymphocytic_B-ABC_aged-B_memory|Lung / Manually curated celltypes from each tissue

LINC01599 ZNF45

3.64e-04164827766900740f67dbbe3c4d90fbfdcc1665cee6515
ToppCellPBMC-Convalescent-Lymphocyte-B-B_cell-B_naive-B_naive-9|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

VAV2 ZNF45

4.24e-0417782ae55773c531099a9e94f44f01ba48b5e71dddc53
ToppCell5'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)-Multiciliated_(nasal)_L.0.3.1.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

CFAP44 GOLGA6L22

4.39e-04180821f1af4474f3f0ac3c0d6b1a6c875c354d36d8eec
ToppCell5'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

CFAP44 GOLGA6L22

4.83e-0418982b4b93bd10b7e3cc16e54ff73beac230f519c010a
DrugTrichostatin A, Streptomyces sp.; Up 200; 0.1uM; MCF7; HT_HG-U133A

CFAP44 ZNF45

1.22e-03176726972_UP
DrugNiclosamide [50-65-7]; Down 200; 12.2uM; HL60; HG-U133A

SMC3 ZNF45

1.39e-03188721998_DN
Drugwortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A

CFAP44 ZNF45

1.40e-03189727002_UP
DrugPenbutolol sulfate [38363-32-5]; Up 200; 5.8uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.46e-03193723534_UP
DrugTrifluridine [70-00-8]; Up 200; 13.6uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.46e-03193727176_UP
DrugPyrilamine maleate [59-33-6]; Down 200; 10uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.47e-03194723184_DN
DrugSulfanilamide [63-74-1]; Up 200; 23.2uM; PC3; HT_HG-U133A

VAV2 CFAP44

1.47e-03194724474_UP
DrugDNA-PK Inhibitor III; Up 200; 1uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.47e-03194727543_UP
DrugICI 182,780; Down 200; 0.01uM; HL60; HT_HG-U133A

CFAP44 ZNF45

1.47e-03194721179_DN
Drug5-aza-2′-deoxycytidine; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

VAV2 ZNF45

1.49e-0319572920_UP
Drugionomycin calcium salt; Up 200; 2uM; MCF7; HT_HG-U133A_EA

VAV2 CFAP44

1.49e-0319572871_UP
DrugCholecalciferol [67-97-0]; Up 200; 10.4uM; MCF7; HT_HG-U133A

VAV2 CFAP44

1.49e-03195723298_UP
DrugNaproxen [22204-53-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A

SMC3 ZNF45

1.49e-03195721706_UP
DrugST021200; Down 200; 10uM; PC3; HT_HG-U133A

VAV2 ZNF45

1.49e-03195727493_DN
DrugQuinacrine dihydrochloride dihydrate [6151-30-0]; Down 200; 7.8uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.49e-03195723179_DN
DrugPentetic acid [67-43-6]; Up 200; 10.2uM; MCF7; HT_HG-U133A

VAV2 CFAP44

1.50e-03196725629_UP
DrugPF-00562151-00 [351320-12-2]; Down 200; 10uM; PC3; HT_HG-U133A

CFAP44 ZNF45

1.50e-03196726863_DN
Drughaloperidol; Down 200; 10uM; MCF7; HT_HG-U133A_EA

VAV2 ZNF45

1.50e-03196721024_DN
DrugLovastatin [75330-75-5]; Down 200; 9.8uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.50e-03196724978_DN
DrugDienestrol [84-17-3]; Down 200; 15uM; MCF7; HT_HG-U133A

VAV2 CFAP44

1.50e-03196723448_DN
DrugDipivefrin hydrochloride [64019-93-8]; Down 200; 10.4uM; PC3; HT_HG-U133A

CFAP44 ZNF45

1.50e-03196727124_DN
DrugBerberine chloride [633-65-8]; Down 200; 10.8uM; PC3; HT_HG-U133A

CFAP44 ZNF45

1.50e-03196727143_DN
DrugSulfacetamide sodic hydrate [6209-17-2]; Down 200; 15.8uM; MCF7; HT_HG-U133A

VAV2 CFAP44

1.50e-03196721695_DN
DrugOxolinic acid [14698-29-4]; Down 200; 15.4uM; PC3; HT_HG-U133A

SMC3 ZNF45

1.50e-03196722103_DN
DrugChenodiol [474-25-9]; Down 200; 10.2uM; MCF7; HT_HG-U133A

VAV2 CFAP44

1.52e-03197726012_DN
DrugBuspirone hydrochloride [33386-08-2]; Up 200; 9.4uM; MCF7; HT_HG-U133A

CFAP44 ZNF45

1.52e-03197722637_UP
DrugCatechin-(+,-) hydrate [7295-85-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A

CFAP44 ZNF45

1.52e-03197723351_UP
DrugMinoxidil [38304-91-5]; Up 200; 19.2uM; MCF7; HT_HG-U133A

CFAP44 ZNF45

1.52e-03197721496_UP
DrugLovastatin [75330-75-5]; Down 200; 9.8uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.52e-03197722854_DN
DrugOxybenzone [131-57-7]; Down 200; 17.6uM; MCF7; HT_HG-U133A

CFAP44 ZNF45

1.52e-03197725410_DN
DrugBucladesine sodium salt [16980-89-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A

VAV2 CFAP44

1.54e-03198723483_DN
DrugMetolazone [17560-51-9]; Down 200; 11uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.54e-03198725392_DN
DrugAH6809; Up 200; 1uM; PC3; HT_HG-U133A

VAV2 CFAP44

1.55e-03199727075_UP
DrugCeftazidime pentahydrate [78439-06-2]; Down 200; 6.2uM; PC3; HT_HG-U133A

VAV2 CFAP44

1.55e-03199725054_DN
DrugPF-01378883-00 [351320-41-7]; Down 200; 10uM; PC3; HT_HG-U133A

VAV2 ZNF45

1.55e-03199726410_DN
DrugOxalamine citrate salt [1949-20-8]; Down 200; 9.2uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.55e-03199723344_DN
Drugclozapine; Up 200; 10uM; MCF7; HT_HG-U133A_EA

VAV2 CFAP44

1.55e-03199721009_UP
DrugImidurea [39236-46-9]; Up 200; 10.4uM; MCF7; HT_HG-U133A

VAV2 ZNF45

1.55e-03199725481_UP
DrugNaproxen [22204-53-1]; Up 200; 17.4uM; HL60; HT_HG-U133A

VAV2 SMC3

1.57e-03200721869_UP
Diseasecolorectal cancer

VAV2 CFAP44

2.44e-0360442MONDO_0005575

Protein segments in the cluster

PeptideGeneStartEntry
EEKIAQMRWELMMKT

CFAP44

1746

Q96MT7
REQEEKMRRQEEMMW

GOLGA6L1

331

Q8N7Z2
KMRRQEEMMWEKEEK

GOLGA6L1

336

Q8N7Z2
EEMMWEKEEKMRRQE

GOLGA6L1

341

Q8N7Z2
EKEEKMRRQEEMMWE

GOLGA6L1

346

Q8N7Z2
MRRQEEMMWEKEEKM

GOLGA6L1

351

Q8N7Z2
EMMWEKEEKMRRLEE

GOLGA6L1

356

Q8N7Z2
KEEKMRRLEEMMWEK

GOLGA6L1

361

Q8N7Z2
QEEKMRRQEEMMWEK

GOLGA6L6

321

A8MZA4
RRQEEMMWEKEEKMR

GOLGA6L6

326

A8MZA4
MMWEKEEKMRRQEEM

GOLGA6L6

331

A8MZA4
EEKMRRQEEMMWEKE

GOLGA6L6

336

A8MZA4
RQEEMMWEKEEKMRR

GOLGA6L6

341

A8MZA4
MWEKEEKMRRQEEMM

GOLGA6L6

346

A8MZA4
EKMRRQEEMMWEKEE

GOLGA6L6

351

A8MZA4
REQEEKMRRQEEMMW

GOLGA6L22

281

H0YM25
KMRRQEEMMWEKEEK

GOLGA6L22

286

H0YM25
EEMMWEKEEKMRRQE

GOLGA6L22

291

H0YM25
EKEEKMRRQEEMMWE

GOLGA6L22

296

H0YM25
MRRQEEMMWEKEEKI

GOLGA6L22

301

H0YM25
EMMWEKEEKIRELEE

GOLGA6L22

306

H0YM25
MDVRAKRQLEIWMEM

LINC01599

11

Q8WXQ3
MERWKNMEKEHMDAI

SMC3

901

Q9UQE7
TEDMKRKWMEQFEMA

VAV2

496

P52735
REEKLWMMKMATQRD

ZNF45

61

Q02386